422 related articles for article (PubMed ID: 34922844)
1. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Nuvvula S; Dahiya S; Patel SA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
4. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B; Miett T; Patel SA
Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
[TBL] [Abstract][Full Text] [Related]
5. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
[TBL] [Abstract][Full Text] [Related]
6. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Olson K; Rizvi S; Fiaschi N; Coetzee S; Wang F; Ullman E; Ahmed HS; Herlihy E; Lee K; Havel L; Potocky T; Ebstein S; Frleta D; Khatri A; Godin S; Hamon S; Brouwer-Visser J; Gorenc T; MacDonald D; Hermann A; Chaudhry A; Sirulnik A; Olson W; Lin J; Thurston G; Lowy I; Murphy AJ; Smith E; Jankovic V; Sleeman MA; Skokos D
Sci Transl Med; 2022 Nov; 14(670):eabn1082. PubMed ID: 36350988
[TBL] [Abstract][Full Text] [Related]
7. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
de Ramon Ortiz C; Wang S; Stathis A; Bertoni F; Zenz T; Novak U; Simonetta F
Hematol Oncol; 2024 Jan; 42(1):e3237. PubMed ID: 37937474
[TBL] [Abstract][Full Text] [Related]
8. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
10. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
Kinoshita H; Bollard CM; Toner K
Semin Hematol; 2023 Nov; 60(5):329-337. PubMed ID: 38336529
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
Gordon MJ; Sureda A; Westin JR
Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
[TBL] [Abstract][Full Text] [Related]
13. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract][Full Text] [Related]
15. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
Dubnikov Sharon T; Assayag M; Avni B; Kfir-Erenfeld S; Lebel E; Gatt ME; Goldschmidt N; Stepensky P; Asherie N; Grisariu S
Br J Haematol; 2023 Jul; 202(1):74-85. PubMed ID: 37070396
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
17. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
Gao J; Dahiya S; Patel SA
Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
19. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
Brooks TR; Caimi PF
Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
